Person › Details

Jan van de Winkel (Genmab A/S (CSE: GEN, Nasdaq: GMAB))

van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)


Organisations Organisation Genmab A/S (CSE: GEN, Nasdaq: GMAB)
  Group Genmab (Group)
  Former/major organisation Medarex Europe B.V.
  Group Bristol-Myers Squibb (BMS) (Group)
Products Product DuoBody technology platform (bispecific antibodies)
  Product 2 Arzerra®

Genmab A/S. (6/24/11). "Press Release: Genmab Announces Zalutumumab Update. Genmab Will Wind Down the Zalutumumab Program – No Impact on Financial Guidance – Zalutumumab Will Be Made Available for Future Partnering". Copenhagen.

Genmab A/S (OMX: GEN) announced today it will wind down the zalutumumab clinical program.

After an extensive search during the first half of the year, the company has not found a satisfactory partnership to take zalutumumab forward in the current climate. As part of the company's disciplined approach and commitment to controlling costs, Genmab will wind down the zalutumumab program. Genmab will continue to pursue partnership leads, but will not invest further in the development of zalutumumab. Cost savings from the wind down will mostly be realized from 2012 and therefore the 2011 financial guidance will not be impacted.

"We have always been focused to ending investment in zalutumumab so that we can concentrate our resources to progress other higher value programs in our pipeline. The product has shown good results in our clinical studies without any serious adverse effects and I believe it has a therapeutic potential; however, we were committed to taking a decision on the future of the product by the end of June and therefore we will now shelve zalutumumab but make it available for partnership should the opportunity arise at some point in the future." said Dr. Jan van de Winkel, CEO of Genmab.

Record changed: 2019-07-14


Picture [LSUK] – The Business Web Portal 650x99px

More documents for Jan van de Winkel

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top